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Influenza is a serious public health problem, since seasonal epi-
demics affect approximately 5-10% of the population and thus 
give rise to a heavy social and healthcare burden. The heavy bur-
den of disease is due to several factors, one of which is the bio-
logical features of the pathogen. Indeed influenza viruses display 
high mutation rates and undergo frequent genetic reassortment. 
Minor variations cause seasonal epidemics and major variations, 
which result from the hybridization of viruses typical of different 
animal species, can lead to pandemics.
Vaccination remains the most efficacious means of mitigating 
the harmful healthcare and social effects of influenza. Influenza 
vaccines have evolved over time in order to offer broader pro-
tection against circulating strains. Trivalent vaccines containing 
two A viruses and one B virus are currently available. However, 
given the co-circulation of both B virus lineages (B/Yamagata and 
B/Victoria), quadrivalent vaccines have recently been developed. 
The new quadrivalent vaccines constitute a great advance, in that 
they can offer broader strain coverage.
Despite the availability of effective and safe influenza vaccines, 
the Italian public’s trust in vaccination has declined and, in 
the last few years, influenza vaccination coverage rates have 
decreased both among the elderly and among at-risk adults. It is 
therefore necessary that users, in their own interests, regain trust 
in this important means of disease prevention.
In order to mitigate the damage wreaked by influenza, it seems 
important to: (i) improve clinical-epidemiological and virological 
surveillance of the disease; (ii) promote the development of new 
efficacious vaccines, as has recently been done through the intro-
duction of the quadrivalent vaccine; (iii) extend free vaccination 
to the entire population, as in the US and Canada; (iv) ensure 
that general healthcare professionals are properly informed and 
always updated with regard to vaccination; (v) promote public 
campaigns to raise the population’s awareness of the importance 
of vaccination; (vi) inform politicians and other decision-makers 
of scientific results in the field of vaccination; (vii) fight the anti-
vaccination lobbies with every available weapon.
ORIGINAL ARTICLE
Influenza vaccination:  
from epidemiological aspects and advances in research 
to dissent and vaccination policies
R. GASPARINI, D. AMICIZIA, P.L. LAI, D. PANATTO
Department of Health Sciences, University of Genoa, Italy 
Keywords
Influenza • Influenza vaccine • Dissent
Summary
Influenza, which is caused by the homonymous virus 
belonging to the Orthomyxoviridae family, is a disease 
characterized by fever, respiratory and other systemic 
symptoms. In both the northern and southern hemi-
spheres, the disease occurs annually, during the cold 
season (seasonal influenza). Periodically – at intervals 
of 20-30 years – antigenically new viruses may appear 
and cause a pandemic [1].
Influenza is a serious public health problem, since sea-
sonal epidemics affect approximately 5-10% of the pop-
ulation and thus give rise to a heavy social and health-
care burden. Influenza-related direct costs are very high 
and mostly linked to severe disease complications and 
deaths, which are usually observed among at-risk sub-
jects (elderly, subjects with chronic diseases and preg-
nant women). Moreover, a typical epidemic peak is as-
sociated with high rates of absenteeism, which, from the 
societal point of view, cause a heavy economic burden 
and hamper public services, especially those offered by 
the National Health System [1].
The heavy burden of disease is due to several factors, 
one of which is the biological feature of the pathogen. 
Indeed, the biology of the influenza virus is complex 
and conditions the epidemiology of the disease. Three 
types of virus are known: A, B and C. While types A 
and C can infect man and many animal species, B vi-
ruses almost exclusively infect humans  [2]. Under the 
electron microscope, the virus generally has a roughly 
spherical shape, from which emerge two glycoproteins 
(hemagglutinin and neuroaminidase) that are essential 
to the biology of the virus [3]. Indeed, these enable the 
virus to adhere to the specific receptors of the cells of 
the respiratory mucosa and allow the release of the virus 
that has multiplied inside the cell [4, 5]. Survival of the 
virus is ensured by the wide variability of its glycopro-
teins (antigens). Specifically, influenza viruses undergo 
very frequent point mutations of the genome, which 
is dispersed in 8 segments of RNA (minor variations). 
This phenomenon occurs in both A and B viruses, while 
the genome of A viruses may undergo far more drastic 
variations (major variations). While minor variations are 
random, major variations are the result of the hybridiza-
tion of viruses typical of different animal species (man, 
swine, birds)  [6]. Theoretically, there are 198 possible 
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combinations of hemagglutinin and neuroaminidase, ac-
cording to the types of the two known glycoproteins [7]. 
If, however, minor variations are considered, the number 
of combinations far exceeds 1 billion. For instance, the 
virus responsible for the last pandemic, which occurred 
in 2009/2010, was the result of a quadruple reassortment 
with two swine virus genes, European and Asian, an 
avian gene and a human gene [8]. A pandemic usually 
displays an atypical epidemiological trend (e.g. young 
adults are particularly affected)  [9] and can, according 
to the pathogenic features of the new virus that causes it, 
determine even millions of deaths [10, 11].
In the last years of the 20th century and the first years 
of the 21st, a considerable challenge was posed by the 
H5N1 virus, which underwent major variations, such as 
H5N6 and H5N8. Moreover, the possibility currently ex-
ists that new subtypes of viruses typical of animals may 
adapt to humans, as in the case of the H7N9 subtype, 
which, from March 2013 to April 2015, caused 662 hu-
man cases and 262 deaths (lethality: about 40%) [12].
Seasonal influenza generally displays a less severe be-
havior. Nevertheless, the World Health Organization 
(WHO) has estimated that the disease causes from 3 to 
5 million cases of severe disease and from 250,000 to 
500,000 deaths each year, worldwide [13].
Vaccination remains the most efficacious means of 
mitigating the harmful healthcare and social effects of 
influenza  [14]. Advances in epidemiology, viral genet-
ics, immunology and molecular biology have given a 
great boost to the preparation of increasingly safe and 
efficacious vaccines. Thus, influenza vaccines purified 
by means of chemical methods and containing whole 
inactivated viruses have given way to split vaccines, 
subunit vaccines, adjuvated vaccines and live attenuated 
vaccines  [15]. Moreover, the high reliance on supplies 
of embryonated hen eggs, which are used in traditional 
vaccine production, has been overcome by the develop-
ment of vaccines obtained by multiplying the virus in 
in vitro cell cultures [16]. However, notwithstanding the 
great progress of vaccinology, vaccine efficacy is blunt-
ed by the great variability of the pathogen and the need 
to update vaccine preparations each year in response to 
the antigen modifications of the virus.
Influenza vaccines have evolved also markedly over 
time in order to offer broader protection against circulat-
ing strains. Indeed, in the early 1960s the vaccine was 
bivalent, i.e. it contained an H3N2 virus and a B virus; 
subsequently, trivalent vaccines containing two A virus-
es and one B virus were developed, and recently, given 
the co-circulation of both B virus lineages (B/Yamagata 
and B/Victoria), quadrivalent vaccines were developed.
The recent availability of quadrivalent vaccines con-
stitutes a great advance, in that they can offer broader 
strain coverage. Indeed, the frequency with which B vi-
ruses were isolated by the Italian NIC (National Influ-
enza Center) in the period 2003-2015 ranged from 0.8% 
to 58.0%, with a mean of 20.5% (95% CI: 0-38%) [17]. 
Thus, considering that influenza cases in Italy vary on 
average from 5 to 6 million each year [18], and assum-
ing 38% frequency of B viruses (the upper value of 95% 
CI) and total B-mismatching, we can suppose that the 
maximum additional percentage of protection provid-
ed by the quadrivalent vaccine may allow us to avoid 
2,280.000 cases (at 100% vaccine efficacy; some stud-
ies  [19,  20] have reported this level of efficacy, albeit 
rarely) or 1,140.000  cases (50% efficacy). This latter 
level of efficacy is closer to that reported in most studies. 
Indeed, a recent meta-analysis conducted by Osterholme 
revealed mean efficacy levels of 59% in subjects aged 
between 18 and 65 years, and of 83% in children aged 
between 6 months and 7 years [21].
Despite the availability of effective and safe influenza 
vaccines, the Italian public’s trust in vaccination has de-
clined. In the last few years, Italian vaccination coverage 
rates have decreased both among the elderly and among 
at-risk adults. In the elderly, vaccination coverage de-
clined from 55.6% in the 2013-2014 season to 49.0% 
in the 2014-2015 season: a fall of  6.6%. However, in 
comparison with the 2005-2006 season, when coverage 
was close to 70% (a rate approaching the ideal cover-
age for subjects aged >  64  years [75%]), the percent-
age drop was much greater (-21%) [22]. It may plausi-
bly be claimed that one of the reasons for this reduction 
was poor communication on the part of the Ministry of 
Health during the pandemic caused by the virus A/Cali-
fornia/07/09 [23]; another may have been the excessive 
prudence of the AIFA, which, for reasons of caution, 
suspended the use of a commercially available vaccine 
for two consecutive years  [24, 25]. These events were 
emotively amplified by the press and mass media, and 
were exploited by anti-vaccination lobbies and con-
sumer associations. As a result, vulnerable subjects were 
not immunized and were therefore more exposed to the 
serious complications of the disease. Thus, it is neces-
sary that users, in their own interests, regain trust in this 
important means of disease prevention. In order to re-
build trust, it must be borne in mind that those who re-
fuse vaccination fall within different categories. Indeed, 
some oppose vaccination on ideological grounds; some 
are skeptical of the utility and safety of vaccines; oth-
ers simply neglect their health, while others again are 
marginalized individuals. There is also a need to raise 
awareness among members of the medical profession, 
since their recommendations are essential to orienting 
patients towards the right health choices.
Moreover, we cannot ignore the fact that the “anti-vac-
cinators” hoodwink the gullible with fantastic false ac-
cusations that are totally bereft of scientific evidence. 
Numerous such fallacies have been circulated, such as, 
for example: “vaccines make women sterile; vaccines 
shrink the ovaries; vaccines cause testicular cancer; vac-
cines are contaminated by amoebas present in the air in 
laboratories; vaccines paralyze the immune system; vac-
cines cause: Alzheimer’s disease, amyotrophic lateral 
sclerosis, multiple sclerosis, transverse myelitis, optical 
neuritis, diabetes, rheumatoid arthritis, asthma; and so 
on and so forth. But the greatest of falsehoods spread by 
the anti-vaccinators is undoubtedly that vaccines cause 
autism. This lie, which masqueraded as the result of a 
scientific study, was put about by Dr. Andrew Wake-
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field in an article published by the scientific journal The 
Lancet [26]. It soon emerged, however, not only that Dr. 
Wakefield had utilized rather unethical para-scientific 
methods, but also that the results served his own person-
al interests; he was subsequently struck off the register 
of British physicians [27]. It is interesting that the anti-
vaccinators’ claims that vaccines cause neurological or 
psychiatric disorders are linked in a subtle manner to the 
“plot hypothesis”. Indeed, these people maintain that the 
plotters (or Illuminated Ones, as they call them) have 
infiltrated all levels of decision-making in order to foist 
mass vaccination on the population. The plotters’ aims 
are said to be twofold. First, they want to stultify the ma-
jority of the world’s people, in order to dominate them 
more easily, and, at the same time, favor unvaccinated 
subjects, whose intellectual skills would remain intact as 
a result of natural selection; second, they want to get rich 
alongside their industrial allies – the vaccine producers.
The American Institute of Medicine (IOM) has repeat-
edly demonstrated that there is no scientific evidence to 
support the much-touted association between vaccines 
and the above-mentioned diseases  [28]. Moreover, in 
most of the neurological diseases of early onset, the ap-
plication of molecular biology to neurology is increas-
ingly revealing the importance of transmissible or new-
onset genetic disorders, and it has been demonstrated 
that cases of disease erroneously attributed to vaccina-
tion, such as Dravet’s syndrome, are actually linked to 
genetic damage [29].
Vaccination is recognized as one of the most cost-effec-
tive in the fight against diseases. However, it is tragic 
that more than 2½ million children worldwide die each 
year, despite efficacious and safe vaccines are currently 
available [30].
In the most advanced countries, such as the USA, vacci-
nation campaigns have always been implemented. How-
ever, when a vaccination strategy works well, its results 
often go unnoticed by the majority of the population. In-
deed, only when events occur that threaten public health 
and arouse mass fears (e.g. measles outbreaks, bioter-
rorist attacks such as that of the envelopes containing 
spores of Bacillus anthracis, or the threat of biological 
weapons), does it become clear just how important it 
is to immunize the population [31]. In Italy, people are 
now beginning to realize this, in the wake of the various 
outbreaks of meningococcal invasive disease that have 
occurred in Tuscany since 2015 [32].
With regard to vaccination policies, it should be pointed 
out that preventive strategies, despite their great suc-
cess, have always been an extremely marginal item of 
expenditure in the Italian National Health Service bud-
get. Indeed, of the total annual expenditure of about 
€ 111 billion, only about € 291 million (0.26%) is spent 
on vaccination (about €  40 million on influenza vac-
cines) [33, 34].
In conclusion, in order to mitigate the damage wreaked 
by influenza, it seems important to strengthen the fol-
lowing interventions:
• improve clinical-epidemiological and virological 
surveillance of the disease;
• promote the development of new efficacious vac-
cines, as has recently been done through the intro-
duction of the quadrivalent vaccine;
• extend free vaccination to the entire population, as in 
the US and Canada [35];
• ensure that general practitioners, pediatricians and 
other healthcare professionals are properly informed 
and always updated with regard to vaccination;
• promote public campaigns to raise the population’s 
awareness of the importance of vaccination, not least 
by using new means of communication such as apps 
for smartphones and tablets [36, 37];
• inform politicians and other decision-makers of sci-
entific results in the field of vaccination [38];
• fight the anti-vaccination lobbies with such weapons 
as: counter-information (e.g. what would happen if 
this or that vaccine had not been invented?), irony, 
satire, humor, logic, scientific evidence and common 
sense.
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